LENNART MUCKE, MD
Neurology at Potrero Ave, San Francisco, CA
License number
California A45116
Category
Neurology
Type
Neurology
Address
Address
1001 Potrero Ave, San Francisco, CA 94110
Phone
(415) 206-8492
(415) 734-2504
(415) 734-2504
Organization information
See more information about LENNART MUCKE at bizstanding.comLennart Mucke MD
1650 Owens St, San Francisco, CA 94158
Industry:
Neurologist
Phone:
(415) 206-8492 (Phone)
Lennart Mucke
Professional information
Lennart Mucke, San Francisco CA
Specialties:
Neurologist
Address:
1650 Owens St, San Francisco, CA 94158
1001 Potrero Ave, San Francisco, CA 94110
1001 Potrero Ave, San Francisco, CA 94110
Education:
Medical Faculty Georg August University, Gottingen - Doctor of Medicine
Massachusetts General Hospital - Residency - Neurology
Massachusetts General Hospital - Residency - Neurology
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Lennart Mucke, San Francisco CA
Specialties:
Neurology
Work:
University of California at San Francisco
1650 Owens St, San Francisco, CA 94158
1650 Owens St, San Francisco, CA 94158
Education:
Albert-Ludwigs-Universitaet Freiburg (1982)
Human Α Synuclein Expressing Transgenic Mice
US Patent:
7459601, Dec 2, 2008
Filed:
May 24, 2004
Appl. No.:
10/853774
Inventors:
Eliezer Masliah - San Diego CA, US
Makoto Hashimoto - La Jolla CA, US
Edward Rockenstein - Chula Vista CA, US
Lennart Mucke - San Francisco CA, US
Makoto Hashimoto - La Jolla CA, US
Edward Rockenstein - Chula Vista CA, US
Lennart Mucke - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01K 67/00, A01K 67/033, A01K 67/027, C12N 5/06, C12N 5/10
US Classification:
800 12, 800 18, 435354
Abstract:
In methods for screening treatments for, and treatment of, neurodegenerative diseases, aggregation in neurons of NACP/α-synuclein is measured and expression of a non-amyloidogenic protein is stimulated in order to reduce the level aggregration. For purposes of screening agents for treatment of neurodegenerative disease, oxidative stress in the neuronal cells is stimulated by introducing a mixture of metal-ions and hydrogen peroxide. Examples of appropriate metals include iron, aluminum, and copper. After introduction of the agent under evaluation for stimulation of expression of non-amyloidogenic protein, the effectiveness is measured by testing for a decrease in the level of aggregation of NACP/α-synuclein. In an exemplary embodiment, the non-amyloidogenic protein is β-synuclein. The aggregation of NACP/α-synuclein is dependent upon the concentration of metal ions in the neuronal cells.
Method Of Screening A Compound For Anxiolytic Activity In An Apolipoprotein E Knockout Animal
US Patent:
2005024, Nov 3, 2005
Filed:
Jul 5, 2005
Appl. No.:
11/175779
Inventors:
Jacob Raber - Portland OR, US
Lennart Mucke - San Francisco CA, US
Lennart Mucke - San Francisco CA, US
International Classification:
A61K048/00, A61K038/17, A01K067/027
US Classification:
514012000, 514044000, 800003000, 800018000
Abstract:
Methods and compositions for use in treating anxiety are provided. In the subject methods, an effective amount of an agent having ApoE3 activity is administered to a host suffering from an anxiety, e.g. excessive anxiety, unwanted anxiety, an anxiety disorder, etc. Also provided are methods and compositions for modulating adrenal steroidogenesis and/or release, particularly stress induced adrenal steroidogenesis and/or release, and the hippocampal-pituitary-adrenal (HPA) axis. In these methods, an effective amount of an ApoE activity modulating agent, e.g. an ApoE agonist or antagonist, is administered to the host.
Methods Of Treating Cognitive Decline Disease Conditions With Androgens
US Patent:
2003013, Jul 24, 2003
Filed:
Sep 27, 2002
Appl. No.:
10/256676
Inventors:
Jacob Raber - Portland OR, US
Lennart Mucke - San Francisco CA, US
Lennart Mucke - San Francisco CA, US
International Classification:
A61K048/00, A61K031/57
US Classification:
514/044000, 514/177000
Abstract:
Methods for treating a host, particularly a female host, for a cognitive decline disease condition are provided. Also provided are methods for improving the cognitive function of a host. In the subject methods, an effective amount of androgenic agent, e.g., a male sex hormone such as testosterone or analogue thereof, is administered to the host, resulting in at least an improvement in cognitive function of the host. The subject methods find use in a variety of different applications, and are particularly suited for use in treating female hosts for neurodegenerative disease conditions, e.g., Alzheimer's disease. Also provided are kits for use in practicing the subject methods.
Methods And Compositions For Reducing Amyloid Beta Levels
US Patent:
8420613, Apr 16, 2013
Filed:
Nov 15, 2007
Appl. No.:
12/447241
Inventors:
Li Gan - San Francisco CA, US
Lennart Mucke - San Francisco CA, US
Lennart Mucke - San Francisco CA, US
Assignee:
The J. David Gladstone Institutes - San Francisco CA
International Classification:
C12N 15/11, A61K 48/00, C07H 21/02, C07H 21/04
US Classification:
514 44A, 536 245
Abstract:
The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.
Method Of Increasing Cathepsin B-Induced Cleavage Of Amyloid-Β Peptides
US Patent:
8388953, Mar 5, 2013
Filed:
Jun 29, 2010
Appl. No.:
12/826403
Inventors:
Li Gan - Burlingame CA, US
Lennart Mucke - San Francisco CA, US
Erik Roberson - Vestavia Hills AL, US
Sarah Mueller-Steiner - Uitikon Waldegg, CH
Lennart Mucke - San Francisco CA, US
Erik Roberson - Vestavia Hills AL, US
Sarah Mueller-Steiner - Uitikon Waldegg, CH
Assignee:
The J. David Gladstone Institutes - San Francisco CA
International Classification:
A61K 38/43
US Classification:
424 9463, 424 94, 530350
Abstract:
The present invention provides a method of increasing cathepsin B-induced cleavage of amyloid-β (Aβ) peptide in a cell or tissue, the method generally involving contacting the cell or tissue with an agent that increases the level of cathepsin B in the cell or tissue. The present invention further provides variant cathepsin B polypeptides that are resistant to inhibition by a cysteine protease inhibitor; as well as nucleic acids encoding the variants, and host cells comprising the nucleic acids.
Methods And Compositions For Reducing Amyloid Beta Levels
US Patent:
7951367, May 31, 2011
Filed:
Nov 15, 2007
Appl. No.:
11/985601
Inventors:
Li Gan - San Francisco CA, US
Lennart Mucke - San Francisco CA, US
Erik Roberson - Vestavia Hills AL, US
Sarah Mueller-Steiner - Uitikon Waldegg, CH
Lennart Mucke - San Francisco CA, US
Erik Roberson - Vestavia Hills AL, US
Sarah Mueller-Steiner - Uitikon Waldegg, CH
Assignee:
The J. David Gladstone Institutes - San Francisco CA
International Classification:
A61K 38/43
US Classification:
424 9463
Abstract:
The present invention provides a method of increasing cathepsin B-induced cleavage of amyloid-β (Aβ) peptide in a cell or tissue, the method generally involving contacting the cell or tissue with an agent that increases the level of cathepsin B in the cell or tissue. The present invention further provides variant cathepsin B polypeptides that are resistant to inhibition by a cysteine protease inhibitor; as well as nucleic acids encoding the variants, and host cells comprising the nucleic acids.
Methods And Compositions For Reducing Amyloid Beta Levels
US Patent:
2013027, Oct 17, 2013
Filed:
Mar 19, 2013
Appl. No.:
13/847092
Inventors:
The J. David Gladstone Institutes - , US
Lennart Mucke - San Francisco CA, US
Lennart Mucke - San Francisco CA, US
International Classification:
A61K 39/395, G01N 33/68, A61K 31/7052, C12Q 1/68
US Classification:
4241331, 435 613, 435 71, 514 44 A, 4241721, 514 178
Abstract:
The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.
Agents That Reduce Neuronal Overexcitation
US Patent:
2014006, Mar 6, 2014
Filed:
Sep 17, 2013
Appl. No.:
14/029604
Inventors:
Lennart Mucke - San Francisco CA, US
Assignee:
The J. David Gladstone Institutes - San Francisco CA
International Classification:
A61K 48/00, C12N 15/113
US Classification:
424450, 514 44 R, 514 44 A
Abstract:
The present invention provides methods of identifying candidate agents for treating excitotoxicity-related disorders. The present invention further provides methods for treating excitotoxicity-related disorders.